Sarepta Seeks FDA Approval for Duchenne Drugs

Sarepta Therapeutics is preparing to request traditional FDA approvals for its Duchenne muscular dystrophy drugs. This move follows mixed trial results, leading to a stock decline as investors assess the drug's prospects. The company faces the challenge of convincing regulators and the market of the drugs' efficacy despite data signals that raise concerns. The outcome will significantly impact Sarepta's pipeline and its position in the rare disease therapeutics market.